A New Era in Cancer Immunotherapy with Tom Whitehead and Dr. Alex Marson

When his six-year-old daughter was diagnosed with acute lymphoblastic leukemia, Tom Whitehead was determined to do whatever it took to save her life. In 2012, Emily Whitehead became the first patient enrolled in a clinical trial of a new immunotherapy treatment known as CAR T, which would ultimately turn her immune system into a powerful weapon against cancer. A decade later, this cancer treatment is now widely used and has gone on to save hundreds of lives. Today, in this special double episode of For Your Innovation, you’ll not only hear from Tom Whitehead as he shares the details of their miraculous story, recounting the innovative research, faith, and support that got them through the most difficult time of their lives, but you’ll also gain additional insight into CAR T therapy from biologist and infectious disease physician, Dr. Alexander Marson. Dr, Marson is a Professor at UCSF and the Director of the Gladstone-UCSF Institute of Genomic Immunology. His lab focuses on adapting CRISPR genome editing techniques to human immune cells in order to understand the genetic programs controlling immune cell function and to manipulate T cells to generate cell-based therapies for a wide range of diseases, including cancer. For a fascinating look at the patient/family/caregiver experience of cancer immunotherapy, intersected with that of a scientist who works on these novel and innovative therapies every day, listen to today’s episode!

“T-cells are a central cell type that we can engage in a number of different ways to start orchestrating responses to treat cancer.” — @MarsonLab Key Points From This Episode: